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Summary.-A retrospective study on 190 children with acute lymphoblastic
leukaemia and marrowrelapse ontherapydemonstrated auniversally poorprognosis
with a high risk of extramedullary leukaemia. 49-1% of children achieved a second
remission, the median duration of haematological remission being 97 days. The
median duration of survival was 157days, with no survivors beyond 2 years 3 months
from relapse. Children with high white blood counts at diagnosis, those relapsing early and older children had a particularly poor prognosis.
Children who achieved a first remission with difficulty and those receiving regular vincristine and prednisolone in their first remission were less likely to achieve a
second remission. Those who failed to go back into remission with the more com-
monly used drugs were not usually responsive to other drugs.
THE INITIAL MANAGEMENT of children
with acute lymphoblastic leukaemia
(ALL) is now conducted according to
generally accepted principles (Mauer &
Simone, 1976). However, there is less
agreement about the management of the
many children who relapse while on treat-
ment. Cornbleet & Chessells (1978) suggest that more aggressive conventional chemo-
therapy will probably not substantially improve the outcome inpatients who have
already had a marrow relapse on treat-
ment. Rivera et al. (1976), however, sug-
gest that results may be improved by intensifying the continuation phase of
treatment. Prolonged second remissions
have only occurred in patients who were
initially under-treated by modern stan-
dards or who were off treatment at the
time of relapse (Cornbleet & Chessells,
1978; Rivera et al., 1976; Aur et al., 1972;
Jacquillat et al., 1973; Leventhal et al.,
1975; George et al., 1979). As only a small
number ofthe available effective cytotoxic drugs are used during the first remission,
there is a theoretical possibility that
failure to prevent relapse may be followed
by the successful use of other effective
cytotoxic drugs. The outcome for children
treated afterrelapse with multiple chemo
therapeutic agents is not well doeu
mented. In a recent article Rivera et al.
(1978) suggested that a second remission
was obtainable in most children relapsing
on treatment, but that the remission
duration was very short.
The major aim of treatment in ALL is
the permanent eradication of the disease.
At present this is only possible in about
50% of children. For the rest, at some
stage the objectives of treatment will
change; thephysician will want to balance
the intensity of treatment against the
quality of survival for each individual
child. This is easiest to achieve when the
eventual outcome is clear. Studies on
children relapsing with leukaemia should
also provide the basis for a rational
approach to investigating new forms of
treatment.
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With this in mind, we studied the
records of all children with ALL treated
in 9 major centres in England and Wales,
who ended their first complete remission
with haematological relapse while still on
treatment.
METHOD
The study was confined to children under
the age of 14 years with ALL who had
received induction therapy, adequate central
nervous system prophylaxis and combination
therapy with at least 2 effective agents until
the time of relapse. Information was ab-
stracted from the notes ofall children in their
first complete remission known to have had a
haematological relapse on treatment up to
31 December 1977. We studied children
being treated at the Children's Hospital,
Ladywood, Birmingham (16); the Royal
Hospital for Sick Children, Bristol (15);
Llandough Hospital, Cardiff (9); Alder Hey
Children's Hospital, Liverpool (24); the
Hospital for Sick Children, Great Ormond
Street, London (37)*; St Bartholomew's
Hospital, London (16); Royal Manchester
Children's Hospital, Pendlebury (61); Not-
Reported separately (Cornbleet & Cliessells, 1978).
Proportion
tingham Children's Hospital (4); and the
Children's Hospital, Sheffield (8).
Factors studied included clinical and
haematological findings at the time of diag-
nosis of ALL, and before and after relapse.
With the aid of an ICL 4-75 computer pro-
gram, we used life tables and the logrank
test to investigate the effects of these factors
(Peto et al., 1976, 1977). We studied survival
from relapse, the proportion of children
achieving a second remission and the dura-
tions of the second haematological and com-
plete remissions.
RESULTS
Four of the 190 children studied (2-1%)
had relapsed with a non-lymphoblastic
leukaemia. The overall probability of
achieving a second remission was 49-1%
(Fig. 1). A small proportion of children
survived for up to I year 4 months in
relapse. For those 93 children who
achieved a second remission, the median
duration of haematological remission was
97 days, and of complete remission 80
days. The risk of death in the second
remission was 29-5%. Twenty of 84
children (25-6%) who relapsed a second
time achieved a third remission. Two of 1.7
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children (11-8%) who relapsed a third
time achieved a fourth remission: both
subsequently died in their fourth relapse.
The median duration of survival for the
whole group of 190 children was 157 days.
There were no survivors beyond 2 years
and 3 months from relapse (Fig. 2).
Fifteen children had a simultaneous
meningeal relapse, 9 boys a simultaneous
testicular relapse and I boy a combined
meningeal, testicular and medullary re-
lapse.
There were small but significant differ-
ences in outcome between 4 of the centres
in the study, but, these did not affect anv
other factors.
ll'BC at diagno,3i,3 and length offir-st
remi-s8ion
Children with a high white blood count
(WBC) at diagnosis had a shorter survival
after relapse (X2 test for trend P < 0-001;
see Fig. 3). This was independent of age,
sex, the number of drugs used to induce
the first, remission and the length of the
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survival (X
2 test for trend P < 0
-00I ; see
Fig. 4). This was independent of the
initialWBCbyretrospectivestratification;
however, there is a relationship between
these factors, children relapsing earlier
tending to have a higher initial WBC
(P<0-001; see Fig. 5). Neither of these
two factors influenced the chances of
attaining a second remission, but children
with ahigh WBC atdiagnosis had a shorter
second remission (P < 0-025).
Age
Children over the age of 1, I years had a
shorter survival following relapse
(P < 0-05) which was independent of the
WBC at diagnosis but not the length of
first remission. These older children were
also less likely to achieve a second re-
mission (P < 0-05).
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first remission by retrospective stratifica-
tion. The length of the first remission was
related to survival following relapse: the
shorter the first remission, the shorter the
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attain a second remission (P < 0-020'$
< 0-005respectively).
Meningeal leukaemia
The presence ofmeningeal leukaemia at
diagnosis in 8 children was associated
with a shorter duration ofhaematological
(but not complete) remission following
relapse (P <0-05) and this was indepen-
dent of the initial WBC by retrospective
stratification.
Otherfactors beforerelapse
The haemoglobin, platelet count, degree
of hepatosplenomegaly, presence of a
mediastinal mass at diagnosis, sex, year
ofdiagnosis, and the schedule ofdrugs to
maintain the first remission (continuous
or intermittent) had no significant effect
on the outcomefollowingrelapse.
Factorsfollowingrelapse
Children receiving more than 4 drugs
to achieve a second remission were very
much less likely to go into remission
(P < 0
-000I ; see Fig. 6). There was no
Drugs usedbeforerelapse
There were 33 children requiring 4 or
more drugs to induce a first remission.
Fifteen ofthese received 4 drugs on inten-
sive protocols because of poor risk factors
at diagnosis. The others went into re-
mission after a mean period of 12 weeks
(range 54-127 days); only 22-2% of these
18 children attained a second remission
(a significantly reduced chance, P <0-05).
The lymphoblasts of 3 children at diag-
nosis had the characteristics of neither T
nor B cells, and did not react with anti-
ALL serum (Greaves et al., 1975). One
child had lymphoblasts that formed E
rosettes with sheep erythrocytes (i.e.
T-cell leukaemia). Cell surface markers
were not examined in the remaining 14
children. The 18 children had similar
WBCs at diagnosis to other children.
However, they tended to relapse early
(P <0-05).
Children whose first remission was
maintained with 2 or 3drugs, and children
treated on protocols where the remission
was maintained without vineristine and
prednisolone pulses, were more likely to
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major difference in the risk of death in
relapse.
No attempt was made to express the
degree of exposure to each drug, which
could vary considerably. Children re-
ceiving vineristine, prednisolone and high-
dose methotrexate were no more likely to
go into remission than those who did not
(X2 0-041, 0-138 and 0-865 respectively).
However, use of the following drugs was
associated with a reduced chance of
attaining asecond remission: asparaginase,
cytosine arabinoside, thioguanine, metho-
trexate, cyclophosphamide, adriamycin,
daunorubicin, and 6-mereaptopurine
(P < 0-025, 0-001, 0-001, 0-05, 0-001, 0-001,
0-01 and 0-025 respectively).
DISCUSSION
This multicentre study demonstrates
the short life expectancy in children with
ALL following marrow relapse while re-
ceiving modern treatment. This contrasts
with the outcome when relapse is confined
to the central nervous system (Gribbin
et al., 1977) except when disease is quickly
followed by haematological relapse. It
also contrasts with the outcome following
haematological relapse after cessation of
maintenance therapy (Cornbleet &
Chessells, 1978; George et al., 1979). From
our study it can be said that marrow
relapse on treatment has a uniformly fatal
outcome. The 49% of children attaining a
second remission in our series was a con-
siderably smallerproportion than the 85%
reported by Rivera et al. (1978) in 56
children relapsing on treatment. However,
none of the children in their series had
received vineristine and prednisolone
pulses during remission maintenance; lack
of exposure to these two drugs before
relapse improved children's chances of a
second remission in our series. If the
addition of these drugs, as has been sug-
gested (Aur et al., 1973; Simone, 1976),
makes no difference to the relapse rate
when given with combination chemo-
therapy, the major effect of their use is to
reduce the chance of a second remission.
The median duration of the second re-
mission (2 months) reported by Rivera
et al. (1978) maintained with 2 agents (one
or both of which were used to maintain
the firstremission) was nolonger than that
of unmaintained first remissions (DeVita
et al., 1975). The median duration of
haematological remission in our series (97 days) was only slightly longer, with a
variety ofdrug regimes.
Four children relapsed with non-
lymphoblastic leukaemia. This may repre-
sent the development of a true second
malignancy, or a second blast crisis in
chronic myeloid leukaemia (Janossy et al.,
1976).
We were not surprised to find differ-
ences in outcome between centres. The
intensity of treatment given when the
expected outlook is poor depends on the
philosophy of the physician as well as the
wishes of the child and family (Kearney, 1977).
The effect of the initial WBC on prog- nosis extends beyond haematological re-
lapse, but is small. The length of the first
remission independently affects survival
to a similar extent. A-n excess of children
with high initial WBCs was found only in
those relapsing in the first year (Fig. 5). This confirms the findings of others
(George et al., 1979; MRC, 1977) that the
adverse prognosis associated with a high WBC at diagnosis diminishes with time.
The independent effect of the duration of
the first remission suggests that the
disease has an inherent tempo, unrelated
to other features of the disease or to
therapy.
Older children fare worse in their first
remission (Simone et al., 1975). The results
in our 11-13-year age group suggest that
the unfavourable prognosis in older child-
ren continues after haematological re-
lapse, independently of initial WBC. We
did not establish a difference in prognosis for children under the age of 2 years at
diagnosis, but there were only 10 such
children in our series.
There appears to be a small group of 18
children who achieved a first remission896 P. J. KEARNEY, J. H. BAUMER AND B. C. HOWLETT
only with difficulty. Although they did
not have particularly high WBC at diag-
nosis, they tended to relapse early. After
relapse, only a minority attained a second
remission. This group ispossibly similar to
the children with "null cell" leukaemia
described by Chessells et al. (1977).
The only two factors at diagnosis which
have been shown to affect the duration of
remission after relapse are initial WBC
and the presence of meningeal leukaemia
atdiagnosis. As there were only 8 children
with meningeal leukaemia at diagnosis in
our series, the independent effect of this
factor on the duration of haematological
remission should be interpreted with
caution.
The number of drugs used to attain a
second remission had a marked effect on
the chances of attaining it. The fact that
children receiving more than 4 drugs had
such a poor chance ofgoing into remission
is strong evidence that children resistant
to the more commonly used drugs are
likely to be resistant to others.
There was an adverse effect on outcome
with most of the drugs used to achieve a
second remission. We believe that this was
because they were used on children who
had already failed to go into remission
with other drugs. Children receiving vary-
ing numbers ofdrugs had a similar risk of
death inrelapse (Fig. 6).
New approaches to treatment, such as
marrow transplantation (Thomas, 1978)
would seem justifiable in selected cases;
but this is feasible for few children re-
lapsing at present. The alternatives are
palliativetherapy orusingprotocols to test
hypotheses about relapse. Prospective
trials of asparaginase (Kung et al., 1978),
glutaminase (Spiers & Wade, 1976),
asparagine synthetase inhibitors (Uren
et al., 1977) and high-dose methotrexate
(Frei et al., 1975) could be compared to
more conventional therapy (e.g. vincris-
tine, prednisolone, adriamycin and cyclo-
phosphamide).
We cannot in a retrospective study of
this sort make any claims as to the value
of individual drugs. However, reinduction
therapy with vineristine andprednisolone,
with or without other drugs, should
usually be successful in children who have
not had periodic exposure to these two
drugsduring the first remission. High-dose
methotrexate was used in only 12 child-
ren, and then was given in combination
with an average of only 3 other drugs.
Therefore its association with a relatively
high proportion of children (7/12) attain-
ing a second remission may be because it
was given early in relapse. However, its
use warrants further investigation in this
situation. Similarly, prospective studies
should help to evaluate the role of main-
tenancetherapy, as there is as yet nogood
evidence that maintenance therapy pro-
longs a second remission. Advances in
treatment can then be quickly established
and ineffective combinations promptly
abandoned.
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